Development of the Virtual Unified Huntington's Disease Rating Scale

The Huntington Study Group currently holds the registered trademark for the Unified Huntington's Disease Rating Scale. The UHDRS® is a research tool which has been developed by the HSG to provide a uniform assessment of the clinical features and course of HD. The UHDRS® has undergone extensive reliability and validity testing and has been used as a major outcome measure by the HSG in controlled clinical trials.The purpose of this research study is to determine if a standard HD assessment (the UHDRS®) is as reliable when conducted virtually as it is when conducted at an in-person visit (vUHDRS)

Inclusion Criteria:Are male or female and 18 years or older at the time of signing the informed consentAre able and willing to provide written informed consentAre English speakingCurrently exhibit motor signs and symptoms of Huntington DiseaseHave a genetic diagnosis of HD with an expanded CAG repeat (greater than or equal to 36) in the huntingtin (HTT) gene at or before Screening/Baseline visit from a validated laboratoryHave oral and written communication skills that are sufficient/adequate to complete all cognitive assessmentsAre ambulatory, but may use any assistive device or require helpAre able to maintain stable medications for 30 days prior to Screening/Baseline through the second in-person visitHave a study partner available to help with technology and set-up and to attend all study visitsHave the ability to get email on the device used for the studyExclusion Criteria:Are unable to complete cognitive or functional assessments due to inability to communicateAre unable to obtain satisfactory internet connection (i.e., internet connection must be stable and support the audio and video needs without freezing or interruption) at home or designated location, even with provided equipmentHave inadequate space at home to assess 10 steps for gait assessmentsHave active suicidal ideation endorsed with a score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) if the ideation occurred within 1 year of Screening or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS if the attempt or acts were performed within 1 year of Screening/Baseline, or participants who, in the opinion of the Site Investigator (SI), present a serious risk of suicide.Have received gene therapy or an investigational drug within 30 days or 5 half-lives, whichever is longer, of the Screening/Baseline visit or plan to use an investigational drug during this study.